Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells

Fig. 5

CT26-CD46 cells can establish tumours in immunocompetent mice. Balb/c mice were injected subcutaneously with either 1 × 106 CT26 or CT26-CD46 cells or 5 × 106 CT26-CD46 cells. Athymic mice inoculated with 2 × 106 HCT116 cells using the same method were used as a positive control for luciferase expression. When tumours reached a volume of 70-150 mm3, 5 × 109 VP of EnAd-CMV-Luc were injected intratumourally. Luciferase expression was monitored over 2 weeks following virus injection. a Mouse weights were monitored at regular intervals for 31 days. b Tumour volumes for each treatment group were measured once palpable tumours were apparent. c Mice were imaged for luciferase expression at the indicated time points after intratumoural injection with EnAd-CMV-Luc using an IVIS imager. Conditions were compared to CT26 tumours using one-way ANOVA. *, p < 0.05; ns, not significant. d Paraffin-embedded tumours were sliced into 4 μm slices and stained for human CD46 expression and counterstained with haematoxylin. Scale bars represent 200 μm

Back to article page